Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Debt Issuance
confidence 72%
filed 2026-09-08
EX-99.1
AsiaStrategy announced entry into a "Bitcoin-collateralised credit facility" with an institutional counterparty, described as "among the larger transactions the Company has written to date" on a "committed on a multi-tranche basis." While the Company acts as lender (not borrower), this facility represents a material new direct financial obligation or credit arrangement that generates recurring revenue and materially alters the Company's balance sheet composition and cash flow profile. The facility is structured as a committed credit product with contractual terms and drawdown mechanics, fitting the debt_issuance category as a creation of a new direct financial obligation or credit facility arrangement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This press release announces a major customer win: selection by "one of the world's largest automotive groups" for a Level 3 autonomous driving radar program across multiple brands, with series-production deliveries scheduled to begin Q4 2027. While the disclosure does not fit the specific categories of M&A activity, debt issuance, or earnings results, it represents a material operational and commercial milestone—a significant new customer contract and program that would affect a reasonable investor's assessment of Arbe's commercialization progress and revenue prospects. The forward-looking statements acknowledge execution risks, but the selection itself is a discrete operational event warranting disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-09-08
Item 1.01
The filing discloses entry into material definitive agreements—specifically non-redemption agreements between Andretti Acquisition Corp. II, its sponsor, and third-party investors. These agreements are directly tied to the company's business combination timeline and capital structure, extending the deadline from September 9, 2026 to September 9, 2027 and securing commitments to retain approximately 6.5 million shares in the trust account. While technically a financing/capital arrangement rather than a traditional M&A transaction, the agreements are material to the company's ability to consummate its pending business combination and are disclosed under Item 1.01 (Entry into a Material Definitive Agreement), making them a core component of the M&A process for a SPAC.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces Beamr's strategic partnership with VAST Data as a Technology Partner in the VAST Cosmos Community, with joint go-to-market initiatives and a product demonstration at IBC 2026. The disclosure describes a material business collaboration involving complementary video and data workflows, product integration, and joint commercialization efforts. While not a discrete M&A transaction, the partnership represents a significant operational and strategic business development that would affect a reasonable investor's assessment of the company's growth prospects and market positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This press release announces Yale University IRB approval enabling patient recruitment for Parts B and C of Clearmind's Phase I/II CMND-100 clinical trial, following positive safety results from Part A. The disclosure is a material operational milestone for a clinical-stage biotech company—it represents regulatory clearance to advance a key clinical program at a leading academic medical center and directly enables acceleration of enrollment. While the event is clearly operational/clinical in nature, it does not fit the specific named categories (it is neither an earnings release, executive change, M&A activity, nor a discrete financial event), making `operational_other` the appropriate classification.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-09-08
The 6-K discloses Board approval and ratification of a new employment agreement with Mr. Jie Yang (Jack Yang), Chief Investment Officer and Executive Director, effective August 1, 2026. The agreement specifies compensation terms including an annual base salary of US$360,000, monthly housing allowance up to US$10,000, eligibility for annual bonus, and participation in equity incentive programs. This is a material compensatory arrangement for a named executive officer requiring disclosure under Item 5.02(e) equivalent standards.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This press release announces two significant clinical development milestones for a clinical-stage biotech company: first patient dosed in Australia for AN4035 (initiating a global Phase I trial) and FDA IND clearance with "Study-May-Proceed" letter. These are material operational/regulatory achievements that advance the company's lead therapeutic candidate, but they do not fit the specific event-type categories (not earnings, M&A, exec changes, impairment, litigation, or other named types). The disclosure is clearly operational—a product development and regulatory milestone—making `operational_other` the appropriate classification.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-09-08
Item 8.01
Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026. This is a clear departure of a named executive officer from the company. The disclosure focuses on the termination of employment rather than appointment or compensation arrangements, making exec_departure the appropriate classification.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-08
The 6-K discloses the results of an extraordinary general meeting held on August 26, 2026, with voting outcomes on four resolutions: (1) increase in authorized share capital from US$50,000 to US$1,000,000, (2) adoption of third amended and restated memorandum and articles of association, (3) authorization of transfer agent and registrar to update records, and (4) adjournment authority. All resolutions passed with overwhelming majorities (99.8%+ voting power represented). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the capital increase and charter amendments are material to investors' understanding of the company's capitalization and governance structure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-09-08
EX-99.3
This is a press release dated September 8, 2026, announcing Can-Fite's Q2 2026 (H1 2026) financial results and clinical progress. The exhibit discloses six-month revenues ($0.20M), R&D expenses ($3.45M), G&A expenses ($1.42M), net loss ($4.60M), and cash position ($7.03M), along with condensed consolidated balance sheets and statements of operations. While the release emphasizes clinical milestones (longer-than-anticipated overall survival in the Phase III HCC study, pancreatic cancer Phase 2a results, and psoriasis Phase 3 interim analysis stage), the core disclosure is the periodic financial results for the first half of 2026, making this an earnings release. The clinical updates are material context for investors assessing the company's pipeline value and cash burn trajectory.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 90%
filed 2026-09-08
Item 3.03
La Rosa Holdings announced a 1-for-6 reverse stock split effective September 8, 2026, as a proactive measure to maintain compliance with Nasdaq's minimum bid price requirement and avoid a delisting deficiency notice. The company has not yet received a deficiency notice but is taking preemptive action to ensure continued listing compliance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-09-08
Item 1.01
Elmet Group entered into a definitive Asset Purchase Agreement on September 3, 2026, to acquire substantially all assets and operations of OSRAM GmbH's metal production facility in Schwabmünchen, Germany, including tungsten and molybdenum manufacturing operations. This material acquisition establishes Elmet's first European manufacturing footprint, with an expected closing in Q1 2027 and a purchase price involving €18 million negative base plus working capital adjustments and a €2.5 million vendor loan.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-08
Item 1.01
NMP Acquisition Corp. entered into a definitive Business Combination Agreement on September 4, 2026, with GTS Holdings, LLC to effect a merger that will result in GTS becoming a publicly traded company, valuing GTS at a $400 million enterprise value in an all-stock transaction.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
Reitar announced execution of a non-binding memorandum of understanding (MOU) with ESR Group to explore smart logistics solutions and potential collaboration at ESR's Kwai Chung Logistics Centre. While the MOU is explicitly non-binding and contains no assurance of definitive agreement or implementation, the announcement describes a strategic partnership opportunity involving Reitar's core "Property + Logistics Technology" platform and ecosystem capabilities. This is a material operational/strategic development for a logistics technology company, though the non-binding nature and contingencies temper the certainty of materialization.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
The filing discloses the appointment of Christopher Jensen as Chief Executive Officer and Board member effective September 8, 2026, along with concurrent compensatory arrangements (base salary $450,000, performance bonus, and RSU eligibility). While Edward Chen's resignation as CEO is also mentioned, the principal disclosed action centers on Jensen's appointment to lead day-to-day operations of a Nasdaq-listed company. The filing also discloses a concurrent employment agreement with CFO Young Cho, but Jensen's CEO appointment is the primary event. This is material to investors as it represents a significant leadership change at a recently public company (IPO in June 2026).
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
Scinai announced the conclusion of its option and license arrangements with PinCell regarding PC111 and a strategic refocusing of R&D resources toward its NanoAb platform and CDMO business. This is a material portfolio restructuring decision affecting the company's strategic direction and capital allocation, but does not fit neatly into specific event categories (not an M&A termination, not a workforce reduction, not a specific financial event). The decision to exit PC111 and reallocate resources is an operational/strategic business event that would affect a reasonable investor's assessment of the company's future prospects and capital deployment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-08
Item 1.01
Meshflow Acquisition Corp. (a SPAC) entered into a definitive Business Combination Agreement with HGP Intelligent Energy, LLC, structured as a merger that will result in HGP becoming a publicly traded company under newly formed Delaware holding company Leyte Parent, Inc. The transaction values HGP at $800 million pre-money equity value with pro forma enterprise value of approximately $921 million and is expected to provide approximately $345 million in gross proceeds.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-08
Item 1.01
Healthcare Triangle entered into a Separation and Distribution Agreement and Transition Services Agreement on September 2, 2026, to effect a planned spin-off of its wholly-owned subsidiary Teyame AI Holdings, Inc. The company intends to distribute a minority interest in Teyame's common stock to HCTI shareholders on a pro rata basis, with HCTI retaining majority ownership, and the parties will subsequently operate as separate public companies. This constitutes a material change of control and structural reorganization requiring Form 10 registration and Nasdaq listing approval, making it a material M&A activity under Item 1.01.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-08
The 6-K discloses the issuance of a $933,333 senior convertible promissory note (the "Second Additional Note") on September 8, 2026, convertible into ADSs representing Class A ordinary shares. This is part of a larger securities purchase agreement for up to $30 million in convertible notes. The issuance of convertible debt that dilutes existing shareholders through conversion rights is a classic dilutive issuance under Section 3.02 of the 8-K taxonomy, and the cumulative principal amount issued ($5.063 million to date) is material to a reasonable investor assessing the registrant's capital structure and shareholder dilution.
View raw filing on EDGAR →
6-K
Governance Other
confidence 82%
filed 2026-09-08
EX-99.2
ROBO.AI Inc. scheduled an Extraordinary General Meeting of Shareholders for September 22, 2026, to vote on material governance matters: a 10-fold increase in authorized share capital (from 200 million to 2 billion shares, or from US$400,000 to US$4,000,000 in par value) and adoption of a sixth amended and restated memorandum and articles of association modifying Class A and Class B share rights. The capital increase and charter amendments would materially affect the company's capital structure and governance framework.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-08
Item 1.01
The filing discloses two material dispositions: (1) sale of the Iowa Site for $1.5 million under a definitive agreement with Simple Mining, LLC, and (2) sale of approximately 5,500 proprietary mining machines (the Company's entire legacy fleet) for ~$3.1 million under a binding term sheet with RepairBit, LLC. These are material asset dispositions totaling approximately $4.6 million, representing a significant reduction in the Company's operational assets and generating substantial liquidity. The Iowa Agreement is explicitly a "definitive agreement" under Item 1.01, and the Mining Machine Agreement is described as a "binding term sheet," both triggering disclosure obligations for material dispositions.
View raw filing on EDGAR →
6-K
Exec departure
confidence 75%
filed 2026-09-08
Ms. Yujie Chen resigned as Chief Executive Officer effective September 7, 2026, due to personal reasons. While the filing also discloses the appointment of a new CEO and an independent director, the principal disclosed action is the departure of the sitting CEO. The resignation is material as it represents a change in the company's chief executive leadership, though Ms. Chen remains as Director and Chairperson.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-08
The 6-K discloses results of the Company's 2026 Annual General Meeting held on September 8, 2026. Seven proposals were voted on: Proposals 4–7 (reverse share split authorization, share capital increase, private placement exercises, and auditor reappointment) were approved, while Proposals 1–3 (director redesignation, compensation policy extension, and board committee compensation) were not approved. This is a direct disclosure of shareholder vote outcomes, matching the shareholder_vote_results event type. The approval of a reverse share split and share capital increase are material to investors' assessment of the company's capital structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-08
Item 1.01
Bluejay Diagnostics entered into a Distribution, Co-Marketing & Strategic Partnership Agreement with Lovell Government Services on September 1, 2026, establishing exclusive and non-exclusive distribution rights for federal healthcare markets (VA, DoD, IHS). This material strategic partnership creates scalable commercial infrastructure for accessing the U.S. federal healthcare market—representing approximately $237 billion in combined budgets—contingent on FDA clearance.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-08
The 6-K discloses entry into a VIE Control Master Acquisition Agreement on September 8, 2026, whereby Jin Medical International will obtain contractual control over Huaxia Qiying (the Target) through VIE arrangements with Chenglan Kangxu and related parties. The transaction involves aggregate consideration of US$159.4 million and issuance of 71.3 million Class A ordinary shares, plus ancillary asset and equity transfers. This constitutes a material acquisition activity under Item 1.01 of Form 8-K (or its 6-K equivalent), with substantial financial and operational implications for the registrant's expansion into ginseng-related biological assets and senior-health platform development.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
Suniva announced completion of an $835 million capital raise (debt and equity financing) to fund construction of a second major U.S. solar cell manufacturing facility in Laurens County, South Carolina, expanding capacity from 1 GW to 5.5 GW. While this involves capital raising and financing, the core disclosure centers on a material operational and strategic expansion—a new manufacturing facility with significant capacity growth and job creation. This is disclosed under Item 7.01 (Regulation FD Disclosure) as a press release and is material to investors assessing the combined SUNation-Suniva entity's operational scale and growth trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-08
Item 1.01
SUNation and Suniva entered into a First Amendment to their Merger Agreement dated June 5, 2026, amending material terms of the proposed merger transaction. The amendment modifies key closing conditions, including authorized share increases, stockholder voting requirements, net cash requirements, and related-party loan conversion terms. This constitutes a material amendment to an ongoing M&A transaction that would materially affect investor assessment of the deal structure and likelihood of completion.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
The press release announces Acco Group's receipt of a Corporate Service Provider (CSP) license from Singapore's ACRA and the launch of licensed CSP operations through its subsidiary Accolade IP (SG) PTE. LTD. This represents a material operational and strategic expansion into a new regulated service line in a key regional market. While not a discrete M&A transaction, debt issuance, or executive change, the licensed entry into a new service sector with significant addressable market opportunity (US$2.0 billion, 6.7% CAGR) constitutes a material operational milestone that would affect a reasonable investor's assessment of the company's growth trajectory and market positioning.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-08
The 6-K announces completion of a private placement of 23,000,000 new ordinary shares to three named subscribers (Wang Tingfeng, Wong Sio Chan, and Zhao Jin Hua) at KRW 1,600 per share, raising approximately HKD 194.7 million. This is an unregistered equity issuance that increases share count from 12,582,732 to 35,582,732 shares (183% dilution), materially affecting existing shareholders' ownership and voting power. The proceeds are designated for working capital, and the shares are subject to a one-year lock-up.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-08
Item 3.01
Estrella Immunopharma received written notification from Nasdaq on September 1, 2026, that it failed to meet the minimum market value of listed securities (MVLS) requirement of $35,000,000 for 30 consecutive business days. The company has been granted a 180-day compliance period until March 1, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This news release reports completion of a summer drilling program at IsoEnergy's Larocque East project, with results showing widespread and elevated radioactivity intersections along the Hurricane South Trend. The disclosure details exploration results (10,159 m drilled in 26 holes, with 18 holes returning intervals above 350 cps threshold and 13 holes at 1,000 cps or greater), which are material operational/exploration milestones for a uranium exploration company. While not a discrete M&A, financing, or governance event, the successful expansion of drilling results and the company's characterization of these as "strongest radioactivity to date" represent material progress on the company's primary asset development objective.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This news release announces the maiden Mineral Resource estimate for Collective Mining's Apollo Deposit at its Guayabales Project in Colombia. The disclosure is a material operational milestone for an exploration-stage mining company — the first formal resource estimate for a flagship project represents a significant advancement in the property's development trajectory and would inform investor assessment of the company's exploration success and future value creation potential. While not fitting a discrete named event type, this is clearly an operational/strategic business milestone material to investors in a junior mining exploration company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This news release announces Collective Mining's maiden Mineral Resource estimate for the Apollo deposit at its Guayabales Project in Colombia. The disclosure details a significant exploration milestone—37.0 Mt Indicated and 48.2 Mt Inferred at 2.17 and 1.83 g/t AuEq respectively—representing a material operational and strategic advancement for the company's flagship project. While not a discrete M&A transaction, debt issuance, or financial restatement, this resource estimate is a major operational milestone that would materially affect a reasonable investor's assessment of the company's asset base and development trajectory, particularly given management's stated intent to accelerate permitting and target an environmental license application in H2 2027.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-09-08
EX-99.1
The exhibit reports results of bondholders' meetings held on September 4, 2026, where bondholders of Ecopetrol's 2010 and 2013 domestic bond issuances voted to approve a proposed merger by absorption between Ecopetrol S.A. (surviving entity) and Parque Solar Portón del Sol S.A.S. (absorbed entity). The merger received supermajority approval (74.92% and 80.77% of outstanding principal amounts respectively), constituting a material acquisition/change-of-control event requiring disclosure under Item 1.01 or 2.01 of the 8-K taxonomy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
Pampa Energía announces approval of its Fertilizer Project under Argentina's RIGI (Incentive Regime for Large Investments), with an estimated investment of approximately US$2.7 billion and capacity of 2.1 million metric tons of urea per year. This is a material operational and strategic milestone — a major capital project receiving government incentive qualification — but does not fit the specific categories of M&A activity, debt issuance, or other named event types; it is best classified as a significant operational/strategic development.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-09-08
EX-99.1
This disclosure addresses a preliminary judicial ruling allegedly suspending Sigma Lithium's environmental licenses in Brazil. Although the company denies receiving formal legal communication and asserts the ruling lacks due process, the announcement of a court order targeting the company's operating licenses—even if disputed—constitutes a material legal/regulatory event that would affect a reasonable investor's assessment of operational continuity and regulatory risk. The company's emphasis on continuing operations and its legal defense strategy confirms materiality, though the lack of formal service and the company's confidence in ultimate vindication prevent classification as a more severe terminal event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
Vale's 6-K discloses clarifications regarding media reports that the company has shelved its plans to conduct an IPO of Vale Base Metals, its base metals unit. While the company states no new corporate decision has been made and reiterates prior clarifications that no studies or decisions regarding a potential public offering were underway, the disclosure addresses a material strategic initiative (the potential spin-off/IPO of a significant business unit) that would affect investor assessment of the company's capital structure and strategic direction. This is an operational/strategic matter that does not fit the specific M&A or capital-raising categories but is clearly material to investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.03
The filing discloses the issuance of consolidated obligations (debt securities) totaling approximately $1.095 billion across three separate issuances with trade dates in early September 2026. The Bank explicitly states that "consolidated obligations issuance is material to the Bank," and Schedule A details specific bond and discount note issuances with defined maturity dates, coupon rates, and call provisions. This is a clear creation of direct financial obligations under Item 2.03.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Topeka. Schedule A details five separate debt issuances with trade dates of 09/03/2026 and 09/04/2026, totaling approximately $815 million in principal across fixed-rate and variable-rate instruments with maturities ranging from 2027 to 2033. This is a classic debt_issuance event under Item 2.03, and the registrant explicitly notes that "consolidated obligations issuance is material to the FHLBank."
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-08
Item 2.02
GameStop issued a press release on September 8, 2026 announcing financial results for its second quarter ended August 1, 2026, with net sales of $790.2 million, record operating income of $160.2 million, and net income of $298.7 million, along with an upward revision of fiscal year 2026 Adjusted EBITDA guidance to in excess of $650 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Michael P. Pell was elected as an Ohio member director of the Federal Home Loan Bank of Cincinnati's board of directors for a four-year term commencing January 1, 2027, confirming board leadership continuity.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.03
The FHLB is disclosing the issuance of Consolidated Bonds totaling $100 million in principal ($10 million and $90 million per Schedule A), with trade dates of 9/2/2026 and settlement dates in September and October 2026. This constitutes creation of direct financial obligations under Item 2.03, which is the core definition of debt_issuance. The filing explicitly states that Consolidated Obligations issuance is material to the FHLB, and the $100 million aggregate principal amount represents a material new debt obligation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A itemizes multiple debt securities issued on trade dates in early September 2026, with principal amounts totaling approximately $567 million across various maturities and rate structures. This is a classic debt issuance disclosure under Item 2.03, and the registrant explicitly notes that "consolidated obligations issuance is material to the FHLBank."
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Boston. Schedule A reports three new debt issuances with trade dates in early September 2026, totaling $65 million in principal ($15M, $25M, and $25M), with maturities ranging from 2028 to 2041 and coupon rates from 4.625% to 5.750%. This is a classic Item 2.03 debt issuance disclosure, and the aggregate amount is material to the registrant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with aggregate par value of approximately $895 million across multiple tranches with settlement dates in September 2026. This constitutes creation of direct financial obligations under Item 2.03, meeting the definition of debt issuance. The materiality is evident from the substantial aggregate principal amount and the multi-tranche structure with varying maturities and terms.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Dallas. Schedule A details three specific bond issuances with trade dates in September 2026, including a $505 million variable-rate note and two fixed-rate bonds totaling $35 million. This represents new debt obligations created by the registrant, fitting squarely within the debt_issuance category under Item 2.03.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane brings 20+ years of ophthalmology experience and previously served as Chief Scientific Officer at Ora, Inc. The appointment includes compensatory terms of $350,000 base salary, $75,000 sign-on bonus, 35% performance bonus target, and 55,000 stock options.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-09-08
EX-99.1
The Company completed issuance of 8,400,000 fully paid ordinary shares to MST Financial Services Pty Ltd and sub-underwriters pursuant to an underwriting agreement related to exercise of ATHO class options. This represents a dilutive equity issuance. The cleansing notice under section 708A(5)(e) of the Corporations Act confirms the shares were issued without disclosure to investors under Part 6D.2, which is a hallmark of unregistered or exempt equity offerings. The material scale (8.4 million shares) and capital-raising context make this material to investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-08
Item 8.01
Longevity Health Holdings entered into a Securities Purchase Agreement with Puritan Partners LLC for the issuance of up to $694,445 in aggregate principal amount of 10% senior secured convertible notes, with gross proceeds of up to $625,000. The Company received an initial $375,000 tranche on August 31, 2026, through issuance of a convertible note due February 29, 2028. This is a creation of a new direct financial obligation—a debt instrument with specified interest rate, maturity, and security interests in substantially all Company assets—fitting the debt_issuance category.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-08
Item 2.02
EVI Industries issued a press release on September 8, 2026 announcing financial results for the three and twelve months ended June 30, 2026, disclosing record revenue of $446.6 million (up 15%), record gross profit of $140.7 million (up 19%), and record operating income of $15.7 million (up 14%). This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, reporting quarterly and annual financial results.
View raw filing on EDGAR →